Create Medic (5187) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
5 Aug, 2026Executive summary
Net sales for the six months ended June 30, 2026, increased by 5.6% year-over-year to ¥6,932 million.
Operating profit declined by 38.6% year-over-year to ¥336 million.
Profit attributable to owners of parent dropped 37.0% year-over-year to ¥260 million.
Comprehensive income for the period was ¥814 million, compared to a loss of ¥157 million in the prior year.
Financial highlights
Ordinary profit decreased by 24.2% year-over-year to ¥398 million.
Basic earnings per share for the six months was ¥31.63, down from ¥48.35 year-over-year.
Total assets as of June 30, 2026, stood at ¥20,140 million, nearly unchanged from December 31, 2025.
Net assets increased slightly to ¥16,489 million, with a capital adequacy ratio of 81.9%.
Outlook and guidance
Full-year net sales forecast for 2026 is ¥13,960 million, up 2.5% year-over-year.
Operating profit is projected to decline 24.4% to ¥760 million for the full year.
Profit attributable to owners of parent is expected to decrease 21.5% to ¥560 million.
Basic earnings per share for the year is forecast at ¥68.90.
Latest events from Create Medic
- Net sales grew 3.8% but profit attributable to owners plunged 98% year-over-year.5187
Q3 202422 Jul 2026 - Net sales rose 4.6% and profit attributable to owners of parent jumped 73.9% year-over-year.5187
Q2 202422 Jul 2026 - Net sales rose 3.5% and net profit surged 446.0% year-over-year, with higher dividends declared.5187
Q4 202422 Jul 2026 - Q1 2025 delivered robust profit growth, but full-year net profit is forecast to decline slightly.5187
Q1 202521 Jul 2026 - Strong first-half profit growth and higher sales, with robust full-year outlook.5187
Q2 202521 Jul 2026 - Sales and operating profit rose, but net income fell; full-year growth and higher dividend expected.5187
Q3 202521 Jul 2026 - Sales and operating profit rose, but net profit fell; moderate growth forecast for FY2026.5187
Q4 202521 Jul 2026 - Q1 2026 delivered higher sales but lower profits, with 2026 guidance signaling profit recovery.5187
Q1 202621 Jul 2026